GET DAILY SIGNALSPfizer (PFE): A Closer Look at the Path Toward $34
Key Takeaways
- Pfizer Inc. (PFE) carries a $34 central price target derived from the five verified analyst estimates sitting above the current share price, rather than the broader consensus.
- Those five targets average to roughly $34: Jefferies at $36, CMB International at $35.75, DBS at $35, Scotiabank at $33, and Guggenheim at $31.
- With shares near $30.50, the move to $34 would represent about 11% upside.
- The overall mean across roughly 28 analysts stands near $29.26, spanning a wide $25 to $36 range that highlights notable divergence in outlooks.
- Supporting elements include the oncology and GLP-1 pipeline, cost discipline, and recent upward target revisions, while risks center on patent expirations and declining COVID-related revenue.
Analyst Targets and the Street’s Mixed Signals
Pfizer (PFE) stands out because the broad consensus has lagged the stock’s recent advance toward a 52-week high. Across about 28 analysts tracked by S&P Global, the average price target is approximately $29.26 within a $25–$36 band. Since that overall mean falls below the current price, the $34 figure comes from averaging only the five verified targets above the market level.
Those targets—Jefferies at $36, CMB International at $35.75, DBS at $35, Scotiabank at $33, and Guggenheim at $31—produce a mean near $34.15, which rounds to $34. The spread between the high and low underscores how divided opinions remain. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Recent changes have leaned upward, with JPMorgan lifting its target to $30 from $28, Scotiabank to $33 from $30, Jefferies to $36, and Bank of America to $29 from $27. Guggenheim trimmed its target to $31 from $35 yet kept a Buy rating. Argus Research upgraded to Buy in March 2026.
Current Price Action and the Road to the Target
Shares traded near $30.52 in late October 2026, close to a 52-week high after rising from the low-$20s earlier in the year. Reaching $34 from here would require roughly an 11% gain, modest in percentage terms yet noteworthy after the prior advance and with most targets still below the market price.
Fundamentally, Pfizer is navigating a transition. Second-quarter 2026 revenue reached about $15.03 billion, but the company recorded a GAAP net loss of roughly $248 million amid restructuring and intangible-amortization charges plus lower COVID product sales. The investment thesis now hinges on growth from the Seagen oncology franchise, progress in the GLP-1 and obesity pipeline, newer vaccines, and ongoing cost controls to protect margins.
Elements That Could Support Further Gains
Constructive drivers include a strengthening oncology portfolio, advances in the GLP-1 obesity area, and a pipeline of potential catalysts to offset maturing products. Several analysts raised targets ahead of the November earnings report, reflecting better near-term sentiment. A dividend yield above 5% and a valuation near 10 times forward earnings provide a value cushion, and positive insider activity has appeared over the past quarter. Favorable pipeline updates or stronger guidance could bolster the case reflected in the higher targets.
Obstacles That Could Limit Upside
The main challenge remains the patent cliff, with loss of exclusivity on key products later this decade cited by analysts as a primary reason for caution. Declining COVID revenue from Comirnaty and Paxlovid continues to pressure results, and the recent GAAP loss points to ongoing restructuring costs. With the overall consensus below the current price, valuation has already moved ahead of the average analyst estimate, leaving limited margin for error. A cautious 2027 outlook, pipeline disappointments, or a rotation out of defensive healthcare stocks could slow momentum.
Technical Context and Key Levels
The advance to a 52-week high near $30.50 represents a breakout from a multi-month range, with the $30 level now serving as nearby support. Below that, the $28–$29 zone where the stock consolidated through much of the third quarter offers more substantial support. The $36 analyst high serves as a longer-term reference, while the area around $31, matching Guggenheim’s target, represents the first resistance to clear on a sustained push toward $34.
Time Horizon and Items to Monitor
Analyst targets typically reflect a roughly 12-month horizon, though assumptions differ. The next key catalyst is the third-quarter earnings report in early November 2026, along with management guidance and commentary on the oncology and obesity pipelines. Further analyst revisions, pipeline data, and the full-year 2026 report expected in early 2027 also warrant attention.
Using AI Tools in My Research Process
In my own workflow, I occasionally reference Tickeron’s AI Daily Buy/Sell Signals to monitor how a name like Pfizer is behaving relative to broader market conditions. The system applies artificial intelligence across thousands of stocks and ETFs to generate signals based on technical and market shifts, which can complement traditional analysis when evaluating levels and trends.
Final Assessment
Whether PFE reaches $34 hinges on whether recent momentum can be backed by fundamentals. The target reflects the average of the five analyst estimates above the current price and implies about 11% upside. The oncology and GLP-1 pipeline along with cost discipline underpin the constructive view, while patent expirations, fading COVID revenue, and a consensus below the market price call for caution. With targets spread from $25 to $36, the upcoming earnings report and guidance will provide the clearest near-term test.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PFE in +3.63% Uptrend, advancing for three consecutive days on October 30, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 37 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 43%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 21 of 42 cases over the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.042) is normal, around the industry mean (-1.376). P/E Ratio (39.636) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.056) settles around the average of (0.039) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement